欧美日韩精品无码专区,成年无码av片,成品漫画免登录去广告版,亚洲精品一区国产

Veracyte  
是一家在新興的分子細胞學領域處于領先水平的分子診斷公司。Afirma基因表達檢測可減少不必要的甲狀腺癌手術風險,通過基因表達分類器檢測Afirma基因的表達能降低超過一半以上不必要的甲狀腺癌手術。

Veracyte, Inc., based in South San Francisco, Calif., is a privately held molecular diagnostics company pioneering the field of molecular cytology. The company is focused on discovering, developing and commercializing molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s first product – the Afirma Thyroid FNA Analysis – was launched in 2011 and combines specialized cytopathology assessment with the Afirma Gene Expression Classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer. The company has a global co-promotion agreement with Genzyme, a Sanofi company, to make the Afirma Thyroid FNA Analysis more broadly available. Veracyte is privately held and funded by Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures. Veracyte and Afirma are registered trademarks of Veracyte, Inc. All rights reserved.